(415) 476-0624 (fax)

Box 1270, UCSF; San Francisco, CA 94143-1270

additional websites:

Biopharmaceutical Sciences and Genomics Graduate Program

University of California, Berkeley, BS, 1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine

Chen, IS-Y, DJ Slamon, JD Rosenblatt, NP Shah, SG Quan and W Wachsman. 1985. The x gene is essential for HTLV replication. Science 229:54-58.

Cann, AJ, JD Rosenblatt, W Wachsman, NP Shah and IS-Y Chen. 1985. Identification of the gene responsible for human T-cell leukemia virus transcription regulation. Nature (London) 318:571-574.

Chen, IS-Y, AJ Cann, NP Shah and RB Gaynor. 1985. Functional relation between HTLV x and adenovirus EIA proteins in transcriptional activation. Science 230:570-573.

Shah, NP, W Wachsman, L Souza, AJ Cann, DJ Slamon and IS-Y Chen. 1986. Comparison of the trans-activation properties of the HTLV-I and HTLV-II x proteins. Mol Cell Biol 6:3626-3631.

Wachsman, W, AJ Cann, JL Williams, DJ Slamon, L Souza, NP Shah and IS-Y Chen. 1987. HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science 235:674-677.

Kitado, H, IS-Y Chen, NP Shah, AJ Cann, K Shimotohno and H Fan. 1987. U3 sequences from HTLV-I and -II LTRs confer px protein response to a murine leukemia virus LTR. Science 235:901-904.

Rosenblatt JD, AJ Cann, DJ Slamon, IS Smalberg, NP Shah, J Fujii, W Wachsman and IS-Y Chen. 1988. HTLV-II trans-activation is regulated by two overlapping nonstructural genes. Science 240:916-919.

Denny, CT, NP Shah, S Ogden, C Willman, T McConnell, W Crist, A Carroll and ON Witte. 1989. Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 86:4254-4258.

Shah, NP, ON Witte and CT Denny. 1991. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines. Mol Cell Biol 11:1854-1860.

Lewis, BC, NP Shah, BS Braun and CT Denny. 1992. Creation of a yeast artificial chromosome fragmentation vector based on lysine-2. Genetic Analysis: Techniques and Applications 9:86-90.

Planelles, V, A Haislip, ES Withers-Ward, SA Stewart, Y Xie, NP Shah and IS-Y Chen. 1995. A new reporter system for detection of retroviral infection. Gene Therapy 2:369-376.

Jowett, JB, V Planelles, B Poon, NP Shah, M-L Chen and IS-Y Chen. 1995. The HIV-1 vpr gene arrests infected T-cells in the G2 + M phase of the cell cycle. J Virology 69:6304-6313.

Withers-Ward, E, JBM Jowett, SA Stewart, Y-M Xie, A Garfinkel, Y Shibagaki, SA Chow, NP Shah, F Hanaoka, DG Sawitz, RW Armstrong, LM Souza and IS-Y Chen. 1996. HIV-1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair. J Virology 71:9732-9742.

Shah, NP and CL Sawyers. 2001. Recent success with the tyrosine kinase inhibitor STI-571 - lessons learned for targeted therapy of cancer. Curr Opin Invest Drugs 2:422-423.

Roumiantsev, S, NP Shah, ME Gorre, JM Nicoll, BB Brasher, CL Sawyers and RA van Etten. 2002. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 16:10700-10705.

Shah, NP, JM Nicoll, B Nagar, ME Gorre, RL Paquette, J Kuriyan and CL Sawyers. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.

Shah NP and CL Sawyers. 2003. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukmias. Oncogene 22:7389-7395.

Shah, NP, C Tran, FY Lee, D Norris, P Chen and CL Sawyers. 2004. Overriding imatinib resistance with a novel ABL inhibitor. Science 305:399-401.

Chu, S, H Xu, NP Shah, DS Snyder, SJ Forman, CL Sawyers and R Bhatia. 2005. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105:2093-2098.

Burgess, MR, BJ Skaggs, NP Shah, FY Lee and CL Sawyers. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA: 20102:3395-3400.

Michor, F, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers and MA Nowak. 2005. Dynamics of chronic myeloid leukemia. Nature 435:1267-1270.

Carter, TA, LM Wodicka, NP Shah, AM Velasco, MA Fabian, DK Treiber, ZV Milanov, CE Atteridge, WH Biggs, PT Edeen, M Floyd, JM Ford, RM Grotzfeld, S Herrgard, DE Insko, SA Mehta, HK Patel, W Pao, CL Sawyers, H Varmus, PP Zarrinkar and DJ Lockhart. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA: 102:11011-11016.

Shah, NP. 2005. Loss of response to imatinib: mechanisms and management Hematology (Am Soc Hematol Educ Program) 2005;:183-7.

Young, MA, NP Shah, LH Chao, M Seeliger, ZV Milanov, WH Biggs, DK Treiber, HK Patel, PP Zarrinkar, DJ Lockhart, CL Sawyers and J Kuriyan. 2006. Structure of the kinase domain of imatinib-resistant ABL mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66: 1007-14.

Shah, NP, FY Lee, R Luo, Y Jiang, M Donker and C Akin. 2006. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activation mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 2006 Jan 24; [Epub ahead of print].

Radich, JP, H Dai, M Mao, V Oehler, J Schelter, B Druker, C Sawyers, N Shah, W Stock, CL Willman, S Friend and PS Linsley. 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA: 2006 Feb 13 [Epub ahead of print].

8/22/06